Cullinan Oncology LLC (CGEM) - Total Assets
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) holds total assets worth $402.98 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cullinan Oncology LLC total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Cullinan Oncology LLC - Total Assets Trend (2012–2025)
This chart illustrates how Cullinan Oncology LLC's total assets have evolved over time, based on quarterly financial data. Explore CGEM long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cullinan Oncology LLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Cullinan Oncology LLC's total assets of $402.98 Million consist of 86.3% current assets and 13.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Cullinan Oncology LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Cullinan Oncology LLC.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cullinan Oncology LLC's current assets represent 86.3% of total assets in 2025, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 19.7% of total assets in 2025, up from 0.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cullinan Oncology LLC Competitors by Total Assets
Key competitors of Cullinan Oncology LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Cullinan Oncology LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.28 | 11.62 | 59.98 |
| Quick Ratio | 10.28 | 11.62 | 59.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $326.25 Million | $290.42 Million | $338.72 Million |
Cullinan Oncology LLC - Advanced Valuation Insights
This section examines the relationship between Cullinan Oncology LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.44 |
| Latest Market Cap to Assets Ratio | 1.98 |
| Asset Growth Rate (YoY) | -27.9% |
| Total Assets | $448.37 Million |
| Market Capitalization | $887.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cullinan Oncology LLC's assets above their book value (1.98x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cullinan Oncology LLC's assets decreased by 27.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cullinan Oncology LLC (2012–2025)
The table below shows the annual total assets of Cullinan Oncology LLC from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $448.37 Million | -27.89% |
| 2024-12-31 | $621.82 Million | +28.43% |
| 2023-12-31 | $484.18 Million | -13.71% |
| 2022-12-31 | $561.12 Million | +28.35% |
| 2021-12-31 | $437.19 Million | +103.62% |
| 2020-12-31 | $214.71 Million | +113.72% |
| 2019-12-31 | $100.46 Million | +190.01% |
| 2018-12-31 | $34.64 Million | +1008342.50% |
| 2016-12-31 | $3.44K | +2811.02% |
| 2015-12-31 | $118.00 | -99.28% |
| 2014-12-31 | $16.34K | -28.15% |
| 2013-12-31 | $22.74K | +127.44% |
| 2012-12-31 | $10.00K | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more